NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants.

Hum Vaccin ImmunotherMay 5, 2026 (epub)
Clinical ResearchInfectious DiseasesPreventive Medicine / Public HealthOpen access

Xuan Ying Poh, Shirley Y Y Mah, Aileen Y Y Yeoh et al.

✦ AI-curated · Sources linked

In 30 seconds

The PRIBIVAC study is a randomized controlled trial assessing the immunogenicity of monovalent mRNA, bivalent mRNA, and NVX-CoV2373 vaccines in 176 triple mRNA-vaccinated adults. At day 28, bivalent mRNA vaccines showed the highest neutralization level against the KP.2 subvariant at 91.7%, compared to 84.4% for monovalent mRNA and 81.4% for NVX-CoV2373.

Key findings

  • Bivalent mRNA vaccines boosted neutralization titers against strain XBB.1.16 by 4.1-fold at day 28.
  • Bivalent mRNA vaccines achieved a neutralization level of 91.7% against the KP.2 subvariant.
  • The anti-S decay rate was slower in the NVX-CoV2373 group compared to mRNA vaccines.
  • Neutralization levels waned to similar levels across all groups by 12 months post-vaccination.

Why it matters

Understanding the comparative immunogenicity of different COVID-19 vaccines is crucial for optimizing booster strategies and enhancing protection against emerging variants, which is vital for public health.

Source

PubMed · PMID 42083894Free full text on PubMed Central

Published in Hum Vaccin Immunother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.